Rep. Carolyn Maloney, Chairwoman of the Committee on Oversight and Reform, and Rep. Frank Pallone, Chairman of the Committee on Energy and Commerce, issued a statement Friday announcing the Committees will examine the approval and pricing of Biogen’s (BIIB) Alzheimer’s drug, Aduhelm. “We have serious concerns about the steep price of Biogen’s new Alzheimer’s drug Aduhelm and the process that led to its approval despite questions about the drug’s clinical benefit. We strongly support innovative treatments to help the millions of Americans who suffer from Alzheimer’s disease, but Aduhelm’s approval and its $56,000 annual price tag will have broader implications for seniors, providers, and taxpayers that warrant close examination. Our Committees will be investigating this matter so Congress and the American people can better understand why this drug was approved, how Biogen set its price and what impact this will have on research for future Alzheimer’s treatments and federal health care programs,” they said. Shares of Biogen in premarket trading are down 1% to $343.11.
previous post